24 September 2025 in Neuroscience
Ipsilateral motor pathways projecting from primary motor cortex (M1) to the distal upper limb exist in humans, and activation of these ipsilateral pathways also facilitate corticomotor excitability of the contralateral homologous muscle. Handedness and biological sex potentially influence the motor cortical representations, however their influence on ipsilateral representations remain largely unexplored. Here, we investigated the effects of ipsilateral contraction on hand motor representation size and excitability, and examined whether these effects were dependent on handedness and/or biological sex. In 80 individuals (40 right-handed, 40-left handed, equal males and females), we performed transcranial magnetic stimulation (TMS) to obtain motor threshold and motor map area of the contralateral first dorsal interosseus (FDI) muscle of each hemisphere, at (1) rest and during (2) ipsilateral FDI muscle contraction at approximately 10% of maximum voluntary contraction. Results showed that ipsilateral contraction increased motor map area and decreased motor threshold within M1. These changes were independent of handedness and biological sex, and similar between hemispheres. Our findings demonstrate that an ipsilateral hand contraction increases the size and excitability of motor representations within ipsilateral M1, and these increases are irrespective of one's handedness and biological sex.
1 September 2025 in International Medical Case Reports Journal
This case series highlights the feasibility and tolerability of using controllable pulse parameter Transcranial Magnetic Stimulation (cTMS) in individuals with painful diabetic neuropathy (pDN). cTMS delivers repetitive monophasic pulses, which allows for greater and longer lasting effects compared to traditional repetitive TMS (rTMS). All participants (N = 2) tolerated 10 sessions of cTMS over a two-week period (five days per week) with no discomfort from the stimulation. They reported no pain from the stimulation despite their heightened pain sensitivity as a result of pDN. The cTMS intervention improved their pain and quality of life as determined through questionnaires evaluating pain, depression, anxiety, and other related measures. Notably, cTMS has never been evaluated in diabetic neuropathy, and our data suggest that it is feasible and tolerable in this clinical population. It further proposes a potential therapeutic treatment option for individuals with pDN.
29 July 2026 in SSRN Electronic Journal
Background: Neurophysiological responses to repetitive transcranial magnetic stimulation (rTMS) are highly variable across individuals. Monophasic stimulation using controllable pulse parameter TMS (cTMS) has been shown to enhance corticospinal excitability and increase responder rates in patterned protocols. However, it remains unclear whether these advantages extend to conventional 10 Hz stimulation. Objective: To compare the acute effects of 10 Hz monophasic cTMS and biphasic rTMS on corticospinal excitability and short-interval intracortical inhibition (SICI), and to examine the influence of sex and brain-derived neurotrophic factor (BDNF) genotype. Methods: Thirty-three healthy adults completed three double-blinded, randomized sessions of 10 Hz cTMS, rTMS, and sham stimulation. Motor evoked potentials (MEPs) and SICI were assessed at baseline and 10 minutes post-stimulation. Responders were classified based on changes in MEP amplitude. Results: No significant changes in MEP amplitude or SICI were observed following cTMS, rTMS, or sham, with no effects of sex or BDNF genotype. Responder analyses revealed substantial variability, with similar rates of facilitation following cTMS (61%) and rTMS (64%). Across real stimulation, facilitation was observed in 57% of Val/Val and 68% of Met carriers, indicating no genotype-dependent differences. Conclusion: A single session of 10 Hz cTMS and rTMS produces comparable effects that do not exceed sham. These findings highlight the influence of placebo and inter-individual variability, underscoring the need for controlled and individualized approaches in neuromodulation research.
17 November 2026 in Neuroscience
1 October 2026 in Journal of Pain Research
Purpose: Controllable pulse parameter transcranial magnetic stimulation (cTMS) delivers monophasic pulses that may produce more robust and longer-lasting changes in corticospinal excitability compared to conventional biphasic stimulation. This study is the first to evaluate the efficacy of cTMS in individuals with fibromyalgia (FM). Participants and methods: In this randomized, double-blinded, placebo-controlled study, 32 participants (48.6 ± 12.3 years, 2 M) completed ten sessions of cTMS or placebo stimulation over 2 weeks, targeting primary motor cortex (M1) using a 10 Hz monophasic protocol (2004 pulses). The primary outcome was pain intensity while secondary outcomes included quality of life (PROMIS-29 v2.0), step count, FM impact, mood, and corticospinal excitability. Results: No significant differences between cTMS or placebo stimulation were observed for pain intensity or secondary outcomes. Exploratory within-group analyses identified a ~12% reduction in pain intensity, increased physical activity, as well as improvements in anxiety, depression, and PTSD symptoms following cTMS. However, these within-group changes were not significantly different from those observed in the placebo group. Conclusion: Ten sessions of 10 Hz monophasic cTMS were well tolerated but did not demonstrate superiority over placebo for pain intensity or secondary outcomes in individuals with FM. The within-group improvements following cTMS support further investigation in larger and adequately powered studies to determine whether specific stimulation protocols or patient subgroups may benefit greater from monophasic stimulation.